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S U M M A R Y
Human metapneumovirus (hMPV), discovered in 2001, most commonly causes upper and lower
respiratory tract infections in young children, but is also a concern for elderly subjects and immune-
compromised patients. hMPV is the major etiological agent responsible for about 5% to 10% of
hospitalizations of children suffering from acute respiratory tract infections. hMPV infection can cause
severe bronchiolitis and pneumonia in children, and its symptoms are indistinguishable from those
caused by human respiratory syncytial virus. Initial infection with hMPV usually occurs during early
childhood, but re-infections are common throughout life. Due to the slow growth of the virus in cell
culture, molecular methods (such as reverse transcriptase PCR (RT-PCR)) are the preferred diagnostic
modality for detecting hMPV. A few vaccine candidates have been shown to be effective in preventing
clinical disease, but none are yet commercially available. Our understanding of hMPV has undergone
major changes in recent years and in this article we will review the currently available information on
the molecular biology and epidemiology of hMPV. We will also review the current therapeutic
interventions and strategies being used to control hMPV infection, with an emphasis on possible
approaches that could be used to develop an effective vaccine against hMPV.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Acute respiratory tract infection (ARI) is a leading cause of
morbidity and mortality worldwide. Globally, ARIs were responsi-
ble for about 20% of total deaths in children less than 5 years of age
in 2000 alone; moreover, about 70% of these deaths occurred in
Sub-Saharan Africa and the southern regions of Asia.1 ARIs affect
children regardless of their economic status, with similar incidence
rates in both developed and developing countries, but with a
higher mortality rate in developing countries.2 The risk of
pneumonia is higher in children in developing countries (10–
20%, compared to 3–4% in developed countries).3
A wide range of etiological agents are responsible for
respiratory problems in children.4 Although upper respiratory
tract infections are generally less serious, they nonetheless carry* Corresponding author.
E-mail address: Subrat_kumar@yahoo.com (S. Kumar).
http://dx.doi.org/10.1016/j.ijid.2014.03.1394
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).signiﬁcant societal costs in terms of lost work, lost school days, and
additional health care costs. For this reason, determining the
etiological agents of these infections is important. With decades of
research and epidemiological studies, we have been able to
establish the importance of known viral pathogens like human
respiratory syncytial virus (hRSV), parainﬂuenza virus, inﬂuenza
virus, coronavirus, and rhinovirus. However, despite these studies,
a substantial proportion of respiratory tract infections still cannot
be attributed to any known pathogen.
Human metapneumovirus (hMPV) was ﬁrst discovered in 2001
in the Netherlands, when the virus was isolated from a paediatric
patient who had symptoms similar to those of hRSV infection.5
Since then, hMPV has been detected in 4–16% of patients with
ARIs.6–8 The incidence of hMPV may vary from year to year in the
same area.9 hMPV causes disease primarily in children, but can
infect adults and immunocompromised individuals as well. The
clinical features of the illness caused by hMPV infection range from
a mild upper respiratory tract infection to life-threatening severe
bronchiolitis and pneumonia.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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family is divided into the subfamilies Paramyxovirinae and
Pneumovirinae. The Pneumovirinae subfamily is further divided
into two genera, Pneumovirus and Metapneumovirus. hRSV is placed
under the genus Pneumovirus, while hMPV is placed under the
genus Metapneumovirus. Whole genome analysis has shown that
hMPV exists as two genotypes, A and B. Based upon the sequence
variability of the attachment (G) and fusion (F) surface glycopro-
teins, these two genotypes are further divided into subgroups A1,
A2, B1, and B2. Subgroup A2 is again subdivided into A2a and
A2b.10,11 One study has described a strain that is under major
subgroup A, but does not fall into subgroups A1 or A2, and hence
there may be a new subgroup evolving in the A major subgroup.12
Study of the molecular biology of hMPV advanced signiﬁcantly
with the establishment of reverse genetics platforms, but we still
lack a reliable vaccine to control hMPV infection. Recent ﬁndings in
hMPV molecular virology, diagnosis, and control strategies are
reviewed here.
2. Molecular virology
The hMPV virion is pleomorphic in nature and its size varies
from 150 nm to 600 nm.5 The genomic orientation of hMPV
resembles other members of the Paramyxoviridae family (Figure 1).
The genome organization of hMPV is quite similar to that of avian
pneumovirus (aMPV), particularly type C. The genomes of hMPV
and hRSV closely resemble each other, excluding a few differences
in the order of the genes and the absence of the non-structural
genes from the hMPV genome (Figure 2). For hRSV, the two non-
structural proteins (NS1 and NS2) have been identiﬁed as potent
multifunctional antagonists of the interferon (IFN) signalling
pathways.13 The absence of these proteins may be the reason
for the difference in level of host innate immune response observed
during hRSV and hMPV infections.14 The hMPV genome is
comprised of negative-sense single-stranded RNA and contains
eight genes that code for nine proteins. The order of the genes in
the genome (from 30 to 50 end) is N–P–M–F–M2–SH–G–L. The
proteins are: the nucleoprotein (N protein), the phosphoprotein (P
protein), the matrix protein (M protein), the fusion glycoprotein (F
protein), the putative transcription factor (M2-1 protein), the RNA
synthesis regulatory factor (the M2-2 protein), the small hydro-
phobic glycoprotein (SH protein), the attachment glycoprotein (G
protein), and the viral polymerase (L protein).15 The RNA core isFigure 1. Schematic diagram of the human metapneumovisurrounded by M protein and covered by a lipid envelope. This
envelope contains the three surface glycoproteins (F, SH, and G), in
the form of spikes of approximately 13–17 nm. The core nucleic
acids are associated with the P, N, L, M2-1, and M2-2 proteins and
form a nucleocapsid 17 nm in diameter. With the help of the G and
F proteins, hMPV attaches and fuses to heparan sulphate receptors
on the cell surface. After the fusion process, the viral nucleocapsid
enters into the cytoplasm of the host cell and undergoes
replication. The newly synthesized viral genome assembles with
the viral P, N, L, and M2 proteins, and moves towards the host cell
membrane. The virion now buds out of the cell, with the F, SH, and
G proteins exposed on the outer side of the membrane.16,17 The P
protein acts as a co-factor to stabilize the L protein, allowing the
formation of the virus ribonucleoprotein (RNP) complex during
virus replication. The M protein plays a crucial role in virus
assembly and budding by interacting with the RNP complex. The N
protein encapsidates the viral genome and protects it from
nuclease activity. In addition to regulating viral transcription
and replication, the M2-2 protein plays a major role in virulence by
decreasing the host’s innate immunity.18,19 Like other members of
the Paramyxoviridae family, hMPV interferes with the host’s innate
immune system using speciﬁc mechanisms. The virus antagonizes
cellular responses by regulating pattern recognition receptors,
such as toll-like receptor and retinoic acid-inducible gene-like
receptors and other signalling molecules.20 Infection interferes
with dendritic cell activity and reduces antigen-speciﬁc T cell
activation.21 Thus, virus clearance remains incomplete and the
chances of re-infection occurring increase.
Members of the two genotypes show much less amino acid and
nucleotide similarity (nucleotide 84–86%, amino acid 94–97%)
than members of the same subgroup (A1 and A2, or B1 and B2)
within the same genotype (nucleotide 94–96%, amino acid 97–
99%) based on the F gene sequence.8 Comparing all the subgroups
(A1, A2, B1, and B2), the N gene is found to be most conserved at
both the nucleotide and the amino acid levels (91.2% and 98.4%,
respectively), while the G gene is the least conserved (79% and
59.2%, respectively).22
3. Epidemiology
hMPV has been isolated on all continents and has a seasonal
distribution. The geographic distribution of the various hMPV
genotypes is given in Figure 3. Outbreaks occur mainly in therus particle and the ribonucleoprotein (RNP) complex.
Figure 2. Genomic organization of (a) human metapneumovirus (hMPV) and (b) respiratory syncytial virus (RSV), showing the important differences between the two
viruses. In comparison to hMPV, RSV expresses two extra proteins, NS1 and NS2, differs in the organization of SH and G proteins, and the reading frames for M2 and L overlap
each other. N, nucleoprotein; P, phosphoprotein; M, matrix protein; F, fusion protein; SH, small hydrophobic protein; G, attachment protein; L, large polymerase protein; NS1
and NS2, non-structural proteins 1 and 2.
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hemisphere and June to July in the southern hemisphere.23,24 A
recent study reported that the peak of the hMPV seasonal cases is
observed between March and April following the RSV and
inﬂuenza infection seasons.25 Another study reported that the
hMPV infection season overlaps with that of the RSV infection
season.26 Being a respiratory infection, hMPV is transmitted by
infectious airborne droplets.27 Seroprevalence studies have shown
that a high percentage (90–100%) of children have been infected by
the time they are 5–10 years old, but re-infection can occur
throughout adulthood.5 This may be due to insufﬁcient immunity
acquired during the initial infection and/or due to infection by
different viral genotypes. The incubation period varies from
individual to individual, but is commonly between 3 and 5 days.
During animal experimentation, peak viral titres are seen between
days 4 and 5 in BALB/c mice and cotton rats.28
hMPV is commonly found in the paediatric population, with
high susceptibility rates in children less than 2 years old. hMPV
infection in adults normally shows only mild ﬂu-like symptoms.Figure 3. Geographical distribution of hMPV genotypes. Map showing the geographical d
are divided into four major subgroups (A1, A2, B1, and B2) and each has its own geogHowever, in some adult cases (especially elderly adults), severe
complications such as chronic obstructive pulmonary disease
(COPD) can occur.29 Dyspnoea is more likely in adults as compared
to children.30 hMPV infection has also been reported in several
immunocompromised patients, such as lung transplant recipients,
patients with haematological malignancies, and hematopoietic
stem cell transplant recipients.31,32 Two studies found that both
genotypes of hMPV (A and B) co-circulated during a typical
respiratory virus season,12,33 and frequent re-infections with
different hMPV genotypes occur.34
Risk factors associated with severe hMPV infection include
premature birth, young age, pre-existing nosocomial infection, and
underlying chronic pulmonary, heart, or neural disorders.35
Studies investigating the relationship between genotype and
disease severity in children have not found any signiﬁcant
correlations. Vicente et al. reported that genotype A may be more
virulent that genotype B,36 while Papenburg et al. indicated that it
was genotype B that was associated with severe hMPV infection.37
Compared to hMPV-negative children, hMPV-infected childrenistribution of hMPV genotypes among humans. Human metapneumovirus isolates
raphical localization.
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have a longer stay in the intensive care unit (ICU), and more likely
to have undergone chest radiography. About 40% of children
hospitalized with hMPV infection were found to have underlying
high risk conditions, like asthma and chronic lung disease.38 The
average annual rate of hospitalization was about three times more
in children less than 6 months old (3/1000) compared to children 6
months to 5 years old (1/1000). Nosocomial infection has been
reported in several studies as a mode of transmission.39,40 The
annual rate of hospitalization due to hMPV infection is equal to
that of inﬂuenza and parainﬂuenza 1, 2, and 3 combined,38 and a
recent analysis of an hMPV outbreak in two skilled nursing
facilities showed an 11% mortality rate.41 The severity of disease
caused by this recently discovered virus and the importance of
hMPV pathogenesis and vaccine research is now becoming clear.
Many studies have reported co-infection of hMPV with other
respiratory pathogens, including RSV,42 bocavirus,23 rhinovirus or
enterovirus, parainﬂuenza virus,43 coronavirus,44 inﬂuenza A,45
and inﬂuenza B.46 hMPV co-infection has also been reported during
an outbreak of severe acute respiratory syndrome (SARS).47 Studies
have also found hMPV co-infection with bacterial pathogens like
Streptococcus pneumoniae, Mycoplasma pneumoniae, and Chlamydia
pneumoniae.45 However, the interaction of hMPV with these other
etiological agents is unclear, as co-infection does not seem to affect
hMPV disease severity.10,48 There are conﬂicting reports on the
association between RSV–hMPV co-infection and disease severity;
some studies found that co-infection leads to an increased rate of
ICU admission and hospital stay,49,50 but others found no
association between co-infection and disease severity.51,52
4. Clinical features
The clinical manifestations of an hMPV infection are indistin-
guishable from those of an RSV infection, especially in young
children. hMPV patients are generally diagnosed with bronchioli-
tis, bronchitis, and pneumonia. They show common symptoms like
fever, cough, hypoxia, upper respiratory tract infection, lower
respiratory tract infection, and wheezing.53 However, the most
common causes of hospitalization are bronchiolitis and pneumo-
nia.54 The average duration of fever in hMPV-positive cases is
about 10 days, with a peak during the course of the illness.55 Young
adults with hMPV re-infection show mild cold and ﬂu-like
symptoms, with fever in a small proportion of infected cases.
However, in the case of elderly patients, re-infection can lead to
severe symptoms (such as pneumonitis) and even to death.30 One
study reported that 50% of children with hMPV infection were
diagnosed with otitis media56 and another study reported that
hMPV infection was found in about 8% of children who came to the
hospital with wheezing.57 Wheezing is a common clinical
symptom observed in multiple studies of children with hMPV-
associated lower respiratory tract infections.58 hMPV infections
can lead to asthma exacerbations in small children and adults.31
hMPV acts as an enhancer of COPD59 and patients with COPD are
more prone to hMPV infection.60,61 A few reports have also
suggested that hMPV infection in children may be associated with
a spectrum of central nervous system diseases ranging from febrile
seizures to severe encephalitis.62
hMPV was detected by real-time RT-PCR in asymptomatic
children, but they had signiﬁcantly lower viral loads that those
found in symptomatic children.63 Higher hMPV viral loads were
signiﬁcantly correlated with the course of illness and disease
severity, irrespective of genotype.64 High levels of hMPV viral
shedding lasted from 1 to 2 weeks after acute illness.65,66 hMPV-
associated fatal pneumonia has been indicated in the case of a child
receiving chemotherapy for acute lymphoblastic leukemia.34
hMPV was found to be the sole etiological agent responsible forthe fatal infection of an allogeneic haematopoietic stem cell
transplant patient showing interstitial and intra-alveolar pneu-
monitis with profound alveolar cell damage.32 hMPV infection
during the ﬁrst week after haematopoietic stem cell transplant
may be associated with much higher morbidity and mortality
rates.66 hMPV can cause a range of illnesses in lung transplant
recipients, from a mild upper respiratory tract infection to a severe
lower respiratory tract infection.67,68 In a prospective study
involving patients with severe motor and intellectual disabilities,
the early stages of hMPV infection were characterized by a low to
moderate increase in C-reactive protein (CRP) levels, reduced
peripheral blood lymphocytes, and an elevated monocyte ratio.55
Although the peripheral blood lymphocytes and monocyte ratio
normalized with the mitigation of symptoms, the CRP levels
persisted for some time.55 Along with elevated serum CRP levels, a
few hospitalized children infected with hMPV were also reported
to have leukopenia and leukocytosis.69
5. Pathogenesis
Persistent infection by hMPV may be attributed to a minimal
and late immune response, as well as delayed cytotoxic T-
lymphocyte activity with impaired virus clearance during primary
infection.70 hMPV interferes with superantigen-induced T cell
activation by infecting dendritic cells. Thus, the proliferation of
antigen-speciﬁc CD4+ T cells is restricted and the production of
long-term immunity is impaired.21 Respiratory viruses are known
to modulate cytokine responses. Compared to RSV and inﬂuenza,
hMPV is a less effective inducer of different cytokines like
interleukin (IL)-12, tumour necrosis factor alpha (TNF-a), IL-6,
IL-1b, IL-8, and IL-10.71 hMPV infection induces pulmonary
inﬂammatory changes in BALB/c mice and cotton rats and leads
to an increase in the levels of interleukins (IL-2, IL-8, IL-4),
interferon (IFN-a), macrophage inﬂammatory protein 1a, and
monocyte chemotactic proteins in the bronchoalveolar lavage ﬂuid
and in the lungs. These changes further lead to perivascular and
peribronchiolar inﬁltration and inﬂammation.31,72 The formation
of intra-alveolar foamy and haemosiderin-laden macrophages,
smudge cells, alveolar damage, and hyaline membrane disease are
seen in immunological and histopathological investigations.67 It is
known that hMPV infection induces toll-like receptor-dependent
cellular signalling. However, the role of toll-like receptor-mediated
signalling in the host’s defence against pulmonary hMPV infection
and pathogenesis is unknown. In a recent study, MyD88-deﬁcient
mice were shown to have signiﬁcantly reduced pulmonary
inﬂammation and associated disease compared to wild-type
C57BL/6 mice after intranasal infection with hMPV.73 The
molecular events in the pathogenesis of hMPV are shown in
Figure 4. To date, there is no clear evidence to determine if hMPV
remains limited to the respiratory tract during infection or if the
virus can cause a systemic infection. There is some evidence that
the latter is possible – one study showed the presence of hMPV in
middle ear ﬂuid56 and another showed the presence of hMPV RNA
in the brain tissue of a patient who died of encephalitis,74 but
further investigation is needed.
6. Diagnosis
Various cell lines, such as Vero cells,75 HEp-2 cells, Hep G2
cells,76 293 cells,29 and LLC-MK2 cells5 have been used for the
growth and isolation of hMPV. In a recent study using 19 different
cell lines to grow hMPV, it was shown that the most suitable cell
lines for the growth of hMPV were a human Chang conjunctiva cell
line (clone 1-5C4) and a feline kidney CRFK cell line.77 In cell
culture, hMPV has a slow growth rate, with late cytopathic effects
varying from the rounding of cells and their detachment from the
Figure 4. Molecular events in the pathogenesis of hMPV infection. Virus attachment to toll-like receptors (TLR) of macrophage and/or dendritic cells activates several adapter
molecules of the immune system (TRIF and MYD88), which in turn activates Nuclear factor kappa beta (NFkb). RNA of internalized virus is detected by cytoplasmic RIG1-like
receptor (RLR), which in turn activates NFkb by activation of mitochondrial antiviral signalling protein (MAVS) and transcription activators interferon regulatory factors 3
and 7 (IRF-3 and IRF-7). Finally NFkb and IRFs induce the production of several interferons and interleukins.
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detection of hMPV antigen using anti-hMPV antibody in direct
ﬂuorescence or ELISA-based assays is widely used along with cell
culture methods.75 The sensitivity and speciﬁcity of cell culture
detection methods were found to be 68% and 99%, respectively, as
compared to real-time RT-PCR detection of hMPV.78 Currently, the
use of cell culture for the diagnosis of hMPV infection is uncommon
and molecular methods like RT-PCR and/or real-time RT-PCR are
more widely used.
Two studies have developed and evaluated multiplex PCR
assays with the aim of providing a tool capable of detecting an
increasingly complete panel of respiratory viruses.79,80 With the
development of multiplex RT-PCR (mRT-PCR), it is now possible to
design a more sensitive and rapid assay for the detection of hMPV.
mRT-PCR methods have a sensitivity and speciﬁcity of 100% and
96%, respectively, compared to 54.6% and 100% for rRT-PCR.81
Another advantage of mRT-PCR is the ability to detect co-
infections, even with very low viral loads that are undetectable
via cell culture or immunostaining.82
However, many clinical laboratories do not at present have the
capability to perform routine diagnostic RT-PCR for hMPV
detection. For rapid and accurate diagnosis of hMPV infections,
a combination of immunoﬂuorescence assays and direct ﬂuores-
cent antibody methods is used as the ﬁrst-line of diagnosis,
followed by RT-PCR on the negative samples.83 In the future, the
availability of shell vial centrifugation culture and hMPV
monoclonal antibodies will be of signiﬁcant beneﬁt for the rapid
diagnosis of hMPV in clinical laboratories.
7. Treatment and control strategies
Currently, the treatments available for hMPV infection are
primarily supportive. But a few reports have raised the possibilityof using ribavirin, immunoglobulin, fusion inhibitors, and small
interfering ribonucleic acids for the treatment and control of hMPV
infection.84–91 The different strategies used to treat hMPV infection
are reviewed in Table 1. Several vaccine candidates against hMPV
have undergone testing in rodent models and non-human primate
models. Although they have shown promising results, none has yet
been tested in human volunteers. There may be problems – a heat
inactivated viral vaccine against hMPV enhanced lung disease
when tested in mice.92
T cell epitope vaccines have been shown to reduce immuno-
modulation by hMPV challenge. Murine animals immunized with
an hMPV cytotoxic T lymphocyte epitope vaccine produced less
Th1 and Th2 type cytokines compared to non-immunized mice
following hMPV challenge.93 A few studies have also evaluated
immunization by chimeric vaccines against hMPV infection. When
tested in hamsters and African green monkeys, chimeric vaccines
for hMPV were shown to induce the production of neutralizing
antibodies and confer immunity against a challenge with the wild-
type.94 A subunit vaccine, using the fusion protein of hMPV, has
been shown to induce cross-protective immunity against hMPV
challenge in the hamster.95 Several hMPV F subunit vaccines have
given strong levels of protection when tested in rodents, hamsters,
and non-human primates.96–98 In a recent study, hMPV virus-like
particles (VLPs) mimicking the properties of the viral surface of
both subgroups A and B were tested as a vaccine candidate. When
tested in mice, these VLPs were able to induce a strong humoral
immune response against both heterologous and homologous
strains.99 Although an hMPV-VLP vaccine seems to be a promising
approach, more research is still warranted to develop a vaccine
that will be effective against all of the subgroups of hMPV.
The emergence of plasmid-based reverse genetics systems has
given a signiﬁcant boost to efforts to develop a live vaccine against
hMPV infection.100 Recombinant hMPVs with SH, G, or M2-2 gene
Table 1
Different treatment strategies under development for the prevention of human metapneumovirus (hMPV) infection
Control strategy Product Human/animal
model used
Results Reference
Antivirals Ribavirin Tissue culture assay Ribavirin along with intravenous immunoglobulin was found to have
antiviral activity against hMPV in vitro
84
Human Oral ribavirin combined with intravenous immunoglobulin led to
rapid and complete recovery in an immunocompromised child who
was undergoing chemotherapy for Burkitt’s lymphoma
85
Antibodies Monoclonal antibody Mice On immunization in BALB/c mice, showed signiﬁcantly reduced lung
viral titres, decreased histopathological changes, and decreased
airway obstruction post challenge with hMPV
86
Hamster Monoclonal antibodies against hMPV F protein showed protection
against heterologous hMPV challenge in hamsters
87
Mice Human monoclonal antibody was able to cross-neutralize hMPV and
hRSV and may be used as prophylaxis and therapy for severe hRSV and
hMPV
88
Fusion inhibitors Inhibitory peptides Mice Fusion peptides against heptad repeat A and B domains of F protein
gave protection against lethal hMPV intranasal challenge in BALB/c
mice. Post-challenge there was a signiﬁcant decrease in lung viral
load, pulmonary inﬂammation, levels of proinﬂammatory cytokines,
and airway obstruction
89
RNA interference SiRNA LLC-MK2 cells SiRNA targeting P and N genes of hMPV was able to inhibit replication
of all subgroups of HMPV in vitro
90
Mice Dicer substrate SiRNA reduced lung viral titre post-challenge in mice 91
Inactivated vaccine Heat inactivated vaccine Mice Immunization gave protective immunity against a homologous strain
of hMPV followed by intranasal challenge in BALB/c mice
92
Epitope vaccine T lymphocyte epitope vaccine Mice Immunization reduced viral load, lung pathology, and expression of
Th2-type cytokines (IL-10, IL-4) after hMPV challenge
93
Chimeric vaccine hMPV antigen on
parainﬂuenza vaccine
African green monkeys,
rhesus monkey
Intranasal immunization of African green monkeys induced hMPV-
speciﬁc humoral and cell-mediated immune response and complete
protection from wild-type hMPV challenge. In the rhesus monkey, this
vaccine was found to be sufﬁciently attenuated
94
Subunit vaccine hMPV F subunit vaccine Hamster Intranasal immunization with recombinant human PIV-1 expressing
hMPV F protein vaccine showed high immunogenicity and protection
in comparison to the ones expressing G and SH proteins
95
Cotton rats Immunization showed reduced nasal viral shedding in cotton rats
after hMPV challenge, while the lung pathology was comparable to
that of control mice
96
Syrian golden hamsters Immunization induced high virus neutralization titres against
homologous virus. It also showed signiﬁcantly reduced viral titres in
nasal turbinates
97
Cynomolgus macaques Immunization induced hMPV F speciﬁc antibody response,
neutralizing antibody, and a robust cellular immune response.
However, the induced humoral response waned rapidly over time
98
VLP Virus-like particles (VLPs) Mice Immunization induced cross-protective immunity in mice against
both homologous and heterologous strains, along with reduced viral
titres in the lungs of immunized animals
99
Live attenuated vaccine DM2-2 Hamster Attenuated and protective in hamsters against Wild type hMPV
challenge
18
DG, DSH, DM2-2 African green monkeys DG and DM2-2 were sufﬁciently attenuated. After challenge with
wild-type hMPV, virus shedding in the lower respiratory tract was
undetectable
101
DM2-2 Mice Immunization induced complete protection against challenge with a
homologous strain and cross-protective immunity against a
heterologous strain
102
hRSV, human respiratory syncytial virus; SiRNA, small interfering RNA; IL, interleukin.
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been shown that the deletion of these genes does not affect the
immunogenicity or the antigenicity of the virus.18,101 In a recent
study, a live attenuated vaccine strain of hMPV was developed by
changing the glycosylation site of the F protein. This vaccine was
found to give complete protection against homologous virus
challenge and some protection against heterologous viral chal-
lenge, even with a challenge at 56 days post-inoculation.102 All
these ﬁndings suggest that before an effective vaccine against
hMPV can be developed, more detailed knowledge of the molecular
pathogenesis of hMPV is required.
8. Conclusions
Human metapneumovirus is a relatively recently described
virus1 and hMPV appears to be as dangerous a pathogen as hRSVin terms of morbidity and mortality. As an important respiratory
pathogen, understanding hMPV pathogenesis and molecular
constraints for severe disease is essential for the treatment of
infection and for the development of an effective vaccine against
hMPV. Recent studies using animal models for hMPV infection
and reverse genetics platforms have shed some light on hMPV
pathogenesis and have allowed us to evaluate live vaccine
candidates. Now we need to initiate the clinical trials to evaluate
the different modalities of treatment available for hMPV
infection.
Acknowledgements
The authors are grateful to Dr Nicole Edworthy for her
contribution towards the correction of the English language in
the manuscript.
S. Panda et al. / International Journal of Infectious Diseases 25 (2014) 45–52 51Conﬂict of interest: The authors report no conﬂicts of interest
and have not received any funds for this article.
References
1. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of worldwide
distribution of child deaths from acute respiratory infections. Lancet Infect Dis
2002;2:25–32.
2. Shapiro E. Epidemiology of acute respiratory infections. Semin Pediatr Infect Dis
1998;9:31–6.
3. Broor S, Bharaj P, Chahar HS. Human metapneumovirus: a new respiratory
pathogen. J Biosci 2008;33:483–93.
4. Weigl JA, Puppe W, Grondahl B, Schmitt HJ. Epidemiological investigation of
nine respiratory pathogens in hospitalized children in Germany using multi-
plex reverse transcriptase polymerase chain reaction. Eur J Clin Microbiol Infect
Dis 2000;19:336–43.
5. Van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al.
A newly discovered human pneumovirus isolated from young children with
respiratory tract disease. Nat Med 2001;7:719–24.
6. Turner P, Turner C, Watthanaworawit W, Carrara V, Cicelia N, Deglise C, et al.
Respiratory virus surveillance in hospitalised pneumonia patients on the
Thailand–Myanmar border. BMC Infect Dis 2013;13:434.
7. Lu G, Li J, Xie Z, Liu C, Guo L, Vernet G, et al. Human metapneumovirus
associated with community-acquired pneumonia in children in Beijing, China.
J Med Virol 2013;85:138–43.
8. Lo´pez-Huertas MR, Casas I, Acosta-Herrera B, Garcı´a ML, Coiras MT, Pe´rez-
Bren˜a P. Two RT-PCR based assays to detect human metapneumovirus in
nasopharyngeal aspirates. J Virol Methods 2005;129:1–7.
9. Maggi F, Pifferi M, Vatteroni M, Fornai C, Tempestini E, Anzilotti S, et al. Human
metapneumovirus associated with respiratory tract infections in a 3-year
study of nasal swabs from infants in Italy. J Clin Microbiol 2003;41:2987–91.
10. Williams JV, Harris PA, Tollefson SJ, Halburnt RL, Pingsterhaus JM, Edwards
KM, et al. Human metapneumovirus and lower respiratory tract disease in
otherwise healthy infants and children. N Engl J Med 2004;350:443–50.
11. van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo-Neto E, de Swart RL,
et al. Antigenic and genetic variability of human metapneumoviruses. Emerg
Infect Dis 2004;10:658–66.
12. Boivin G, Mackay I, Sllots TP, Madhi S, Freymuth F, Wolf D, et al. Global genetic
diversity of human metapneumovirus fusion gene. Emerg Infect Dis
2004;10:1154–7.
13. Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus non-structural
proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta
interferon responsiveness. J Virol 2005;79:9315–9.
14. Ditt V, Lusebrink J, Tillmann RL, Schildgen V, Schildgen O. Respiratory infec-
tions by HMPV and RSV are clinically indistinguishable but induce different
host response in aged individuals. PLoS One 2011;6:e16314.
15. Biacchesi S, Murphy BR, Collins PL, Buchholz UJ. Frequent frame shift and point
mutation in the SH gene of human metapneumovirus passaged in vitro. J Virol
2007;81:6057–67.
16. Feuillet F, Lina B, Rosa-Calatrava M, Boivin G. Ten years of human metapneu-
movirus research. J Clin Virol 2012;53:97–105.
17. Chang A, Masante C, Buchholz UJ, Dutch RE. Human metapneumovirus
(HMPV) binding and infection are mediated by interactions between the
HMPV fusion protein and heparan sulfate. J Virol 2012;86:3230–43.
18. Schickli JH, Kaur J, MacPhail M, Guzzetta JM, Spaete RR, Tang RS. Deletion of
human metapneumovirus M2-2 increases mutation frequency and attenuates
growth in hamsters. Virol J 2008;5:69.
19. Ren J, Wang Q, Kolli D, Prusak DJ, Tseng CT, Chen ZJ, et al. Human metapneu-
movirus M2-2 protein inhibits innate cellular signalling by targeting MAVS. J
Virol 2012;86:13049–61.
20. Kolli D, Bao X, Casola A. Human metapneumovirus antagonism of innate
immune responses. Viruses 2012;4:3551–71.
21. Cespedes PF, Gonzalez PA, Kalergis AM. Human metapneumovirus keeps
dendritic cells from priming antigen-speciﬁc naive T cells. Immunology
2013;139:366–76.
22. Piyaratna R, Tollefson SJ, Williams JV. Genomic analysis of four human
metapneumovirus prototypes. Virus Res 2011;160:200–5.
23. Pilger DA, Cantarelli VV, Amentea SL, Leistner-Segal S. Detection of human
bocavirus and human metapneumovirus by real-time PCR from patients with
respiratory symptoms in Southern Brazil. Mem Inst Oswaldo Cruz
2011;106:56–60.
24. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, et al. The association of newly
identiﬁed respiratory viruses with lower respiratory tract infections in Korean
children, 2000–2005. Clin Infect disease 2006;43(5):585–92.
25. Mizuta K, Abiko C, Akoi Y, Ikeda T, Matsuza Y, Itagaki T, et al. Seasonal patterns
of respiratory syncytial virus, inﬂuenza A virus, human metapneumovirus and
parainﬂuenza virus type 3 on the basis of virus isolation data between 2004
and 2011 in Yamagata, Japan. Jpn J Infect Dis 2013;66:140–5.
26. Chan PC, Wang CY, Wu PS, Chang PY, Yang TT, Chiang YP, et al. Detection of
human metapneumovirus in hospitalized children with acute respiratory tract
infection using real-time RT-PCR in a hospital in northern Taiwan. J Formos
Med Assoc 2007;106:16–24.
27. Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev
2006;19:546–57.28. Hamelin ME, Cote S, Laforge J, Lampron N, Bourbeau J, Weiss K, et al. Human
metapneumovirus infection in adults with community-acquired pneumonia
and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis
2005;41:498–502.
29. Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, et al. Virological features
and clinical manifestations associated with human metapneumovirus: a new
paramyxovirus responsible for acute respiratory-tract infections in all age
groups. J Infect Dis 2002;186:1330–4.
30. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus
infections in young and elderly adults. J Infect Dis 2003;187:785–90.
31. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM, et al. A
prospective study comparing human metapneumovirus with other respirato-
ry viruses in adults with hematologic malignancies and respiratory tract
infections. J Infect Dis 2005;192:1061–5.
32. Dokos C, Masjosthusmann K, Rellensmann G, Werner C, Schuler LS, Muller KM,
et al. Fatal human metapneumovirus infection following allogeneic hemato-
poietic stem cell transplantation. Transpl Infect Dis 2013;15:97–101.
33. Duchamp MB, Lina B, Trompette A, Moret H, Motte J, Andreoletti L. Detection
of human metapneumovirus RNA sequences in nasopharyngeal aspirates of
young French children with acute bronchiolitis by real-time reverse transcrip-
tase PCR and phylogenetic analysis. J Clin Microbiol 2005;43:1411–4.
34. Pelletier G, Dery P, Abed Y, Boivin G. Respiratory tract re-infections by the new
human metapneumovirus in an immunocompromised child. Emerg Infect Dis
2002;8:976–8.
35. Principi N, Esposito S. Paediatric human metapneumovirus infection: epide-
miology, prevention and therapy. J Clin Virol 2014;59:141–7.
36. Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Differences in
clinical severity between genotype A and genotype B human metapneumo-
virus infection in children. Clin Infect Dis 2006;42:111–3.
37. Papenburg J, Carbonneau J, Isabel S, Bergeron MG, Williams JV, De Serres G,
et al. Genetic diversity and molecular evolution of the major human metap-
neumovirus surface glycoproteins over a decade. J Clin Virol 2013;58:541–7.
38. Edwards KM, Zhu Y, Grifﬁn MR, Weinberg GA, Hall CB, Szilagyi PG, et al. New
vaccine surveillance network burden of human metapneumovirus infection in
young children. N Engl J Med 2013;368:633–43.
39. Kim S, Sung H, Im HJ, Hong SJ, Kim MN. Molecular epidemiological investigation
of a nosocomial outbreak of human metapneumovirus infection in a pediatric
hemato-oncology patient population. J Clin Microbiol 2009;47:1221–4.
40. Tu CC, Chen LK, Lee YS, Ko CF, Chen CM, Yang HH, et al. An outbreak of human
metapneumovirus infection in hospitalized psychiatric adult patients in
Taiwan. Scand J Infect Dis 2009;41:363–7.
41. Centers for Disease Control and Prevention (CDC). Outbreaks of human
metapneumovirus in two skilled nursing facilities—West Virginia and Idaho,
2011–2012. MMWR Morb Mortal Wkly Rep 2013;62:909–13.
42. Greensill J, McNamara PS, Dove W, Flanagan B, Smyth RL, Hart CA. Human
metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg
Infect Dis 2003;9:372–5.
43. Fathima S, Lee BE, May-Hadford J, Mukhi S, Drews SJ. Use of an innovative web-
based laboratory surveillance platform to analyze mixed infections between
human metapneumovirus (hMPV) and other respiratory viruses circulating in
Alberta (AB), Canada (2009–2012). Viruses 2012;4:2754–65.
44. Esposito S, Daleno C, Prunotto G, Scalla A, et al. Impact of viral infections in
children with community-acquired pneumonia: results of a study of 17
respiratory viruses. Inﬂuenza Other Respir Viruses 2013;7:18–26.
45. Lin TY, Huang YC, Tsao KC, Huang YL. Human metapneumovirus and
community-acquired pneumonia in children. Chang Gung Med J 2005;28:
683–8.
46. Ghattas C, Mossad SB. Fatal human metapneumovirus and inﬂuenza B virus
coinfection in an allogeneic hematopoietic stem cell transplant recipient.
Transpl Infect Dis 2012;14:e41–3.
47. Leung J, Esper F, Weibel C, Kahn JS. Sero-epidemiology of human metapneu-
movirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay
utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis
virus. J Clin Microbiol 2005;43:1213–9.
48. Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, et al. The association of newly
identiﬁed respiratory viruses with lower respiratory tract infections in Korean
children, 2000–2005. Clin Infect Dis 2006;43:585–92.
49. Semple MG, Cowell A, Dove W, Greensill J, McNamara PS, Halfhide C, et al. Dual
infection of infants by human metapneumovirus and human respiratory
syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis
2005;191:382–6.
50. Foulongne V, Guyon G, Rodie`re M, Segondy M. Human metapneumovirus
infection in young children hospitalized with respiratory tract disease. Pediatr
Infect Dis J 2006;25:354–9.
51. Van Woensel JB, Bos AP, Lutter R, Rossen JW, Schuurman R. Absence of human
metapneumovirus co-infection in cases of severe respiratory syncytial virus
infection. Pediatr Pulmonol 2006;41:872–4.
52. Lazar I, Weibel C, Dziura J, Ferguson D, Landry ML, Kahn JS. Human metap-
neumovirus and severity of respiratory syncytial virus disease. Emerg Infect Dis
2004;10:1318–20.
53. Boivin G, De Serres G, Cote S, Gilca R, Abed Y, Rochette L, et al. Human
metapneumovirus infections in hospitalized children. Emerg Infect Dis
2003;9:634–40.
54. Matsuda S, Nakamura M, Hirano E, Kiyota N, Omura T, Suzuki Y, et al.
Characteristics of human metapneumovirus infection prevailing in hospital
S. Panda et al. / International Journal of Infectious Diseases 25 (2014) 45–5252wards housing patients with severe disabilities. Jpn J Infect Dis 2013;66:195–
200.
55. Van den Hoogen BG, van Doornum GJ, Fockens JC, Cornelissen JJ, Beyer WE, de
Groot R, et al. Prevalence and clinical symptoms of human metapneumovirus
infection in hospitalized patients. J Infect Dis 2003;188:1571–7.
56. Williams JV, Tollefson SJ, Nair S, Chonmaitree T. Association of human
metapneumovirus with acute otitis media. Int J Pediatr Otorhinolaryngol
2006;70:1189–93.
57. Jartti T, van den Hoogen BG, Garofalo RP, Osterhaus AP, Ruuskanen O. Metap-
neumovirus and acute wheezing in children. Lancet 2002;360:1393–4.
58. Williams JV, Crowe Jr JE, Enriquez R, Minton P, Peebles Jr RS, Hamilton RG,
et al. Human metapneumovirus infection plays an etiologic role in acute
asthma exacerbations requiring hospitalization in adults. J Infect
2005;192:1149–53.
59. Perotin JM, Dury S, Renois F, Deslee G, Wolak A, Duval V, et al. Detection of
multiple viral and bacterial infections in acute exacerbation of chronic ob-
structive pulmonary disease: a pilot prospective study. J Med Virol
2013;85:866–73.
60. Ilvan A, Aslan G, Serin MS, Calıkoglu M, Yılmaz FM, Tezcan S, et al. Investigation
of the presence of human metapneumovirus in patients with chronic obstruc-
tive pulmonary disease and asthma and its relationship with the attacks.
Mikrobiyol Bul 2013;47:636–49.
61. Jain B, Singh AK, Dangi T, Agarwal A, Verma AK, Dwivedi M, et al. High
prevalence of human metapneumovirus subtype B in cases presenting as
severe acute respiratory illness: an experience at tertiary care hospital. Clin
Respir J 2014;8(2):225–33.
62. Arnold JC, Singh KK, Milder E, Spector SA, Sawyer MH, Gavali S, et al. Human
metapneumovirus associated with central nervous system infection in chil-
dren. Pediatr Infect Dis J 2009;28:1057–60.
63. Bosis S, Esposito S, Osterhaus AD, Tremolati E, Begliatti E, Tagliabue C, et al.
Association between high nasopharyngeal viral load and disease severity in
children with human metapneumovirus infection. J Clin Virol 2008;42:286–90.
64. Peng D, Zhao X, Liu E, Huang Y, Yang X, Zhao Y, et al. Analysis of viral load in
children infected with human metapneumovirus. Iran J Pediatr 2010;20:393–
400.
65. Talaat KR, Karron RA, Thumar B, MacMohan BA, Schmidt AC, Collins PL,
Buchholz UJ. Experimental infection of adults with recombinant wild-type
human metapneumovirus. J Infect Dis 2013;208(10):1669–78.
66. Englund JA, Boeckh M, Kuypers J, Nichols WG, Hackman RC, Morrow RA, et al.
Brief communication: fatal human metapneumovirus infection in stem-cell
transplant recipients. Ann Intern Med 2006;144:344–9.
67. Sumino KC, Agapov E, Pierce RA, Trulock EP, Pfeifer JD, Ritter JH, et al. Detection
of severe human metapneumovirus infection by real-time polymerase chain
reaction and histopathological assessment. J Infect Dis 2005;192:1052–60.
68. Hopkins MJ, Redmond C, Shaw JM, Hart IJ, Hart CA, Smyth RL, et al.
Detection and characterisation of human metapneumovirus from children
with acute respiratory symptoms in north-west England. UK J Clin Virol
2008;42:273–9.
69. Wei YH, Tsao KC, Huang CG, Huang YC, Lin TY. Clinical feature of different
genotypes/genogroups of human metapneumovirus in hospitalized children. J
Microbiol Immunol Infection 2013;46:352–7.
70. Alvarez R, Tripp RA. The immune response to human metapneumovirus is
associated with aberrant immunity and impaired virus clearance in BALB/c
mice. J Virol 2005;79:5971–8.
71. Laham FR, Israele V, Casellas JM, Garcia AM, Lac Prugent CM, Hoffman SJ, et al.
Differential production of inﬂammatory cytokines in primary infection with
human metapneumovirus and with other common respiratory viruses of
infancy. J Infect Dis 2004;189:2047–56.
72. Lara M, Ghosh A, Plata A. Critical role of MDA5 in the interferon response
induced by human metapneumovirus infection in dendritic cells and in vivo. J
Virol 2012;87:1242–51.
73. Ren J, Kolli D, Deng J, Fang R, Gong B, Xue M, et al. MyD88 controls human
metapneumovirus-induced pulmonary immune responses and disease path-
ogenesis. Virus Res 2013;176:241–50.
74. Schildgen O, Glatzel T, Geikowski T, Scheibner B, Matz B, Bindl L, et al. Human
metapneumovirus RNA in encephalitis patient. Emerg Infect Dis 2005;11:467–
70.
75. Tollefson SJ, Cox RG, Williams JV. Studies of culture conditions and environ-
mental stability of human metapneumovirus. Virus Res 2010;151:54–9.
76. Schildgen V, Lusebrink J, Ditt V, Tillmann R, Simon A, Muller A, et al. Human
HepG2 cells support respiratory syncytial virus and human metapneumovirus
replication. J Virol Methods 2010;163:74–81.
77. Isaeva EI, Kozulina IS, Podcherniaeva RI, Grinkevich OM. Reproduction of the
metapneumovirus in different cell lines. Vopr Virusol 2012;57:19–23.
78. Matsuzaki Y, Mizuta K, Takashita E, Okamoto M, Itagaki T, Katsushima F, et al.
Comparison of virus isolation using the Vero E6 cell line with rt RT-PCR assay
for detection of hMPV. BMC Infect Dis 2010;10:170.
79. Pujol BS, Vabret A, Legrand L, Dina J, Gouarin S, Lecherbonnier JP, et al.
Development of three multiplex RT-PCR assays for the detection of 12 respi-
ratory RNA viruses. J Virol Methods 2005;126:53–63.80. Litwin CM, Bosley JG. Seasonality and prevalence of respiratory pathogens
detected by multiplex PCR at a tertiary care medical centre. Arch Virol
2014;159(1):65–72.
81. Bharaj P, Sullender WM, Kabra SK, Mani K, Cherian J, Tyagi V, et al. Respiratory
viral infections detected by multiplex PCR among pediatric patients with
lower respiratory tract infections seen at an urban hospital in Delhi from
2005 to 2007. Virol J 2009;6:89.
82. Choudhury ML, Anand SP, Heydari M, Rane G, Potdar VA, Chandha MS, et al.
Development of a multiplex one step RT PCR that detects eighteen respiratory
viruses in clinical specimens in comparison with real time RT-PCR. J Virol
Methods 2013;189:15–9.
83. Jokela P, Piiparinen H, Luiro K, Lappalainen M. Detection of hMPV and RSV by
duplex real time PCR assay in comparison with DFA. Clin Microbiol Infect
2012;16:1568–73.
84. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the
inhibition of human metapneumovirus and respiratory syncytial virus by
ribavirin and immune serum globulin in vitro. Antiviral Res 2003;60:51–9.
85. Kitanovski L, Kopriva S, Pokorn M, Dolnicar MB, Rajic V, Stefanovic M, et al.
Treatment of severe human metapneumovirus pneumonia in an immuno-
compromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol
2013;35:e311–3.
86. Hamelin ME, Gagnon C, Prince GA, Kiener P, Suzich J, Ulbrandt N, et al.
Prophylactic and therapeutic beneﬁts of a monoclonal antibody against the
fusion protein of human metapneumovirus in a mouse model. Antiviral Res
2010;88:31–7.
87. Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, et al. Isolation and
characterization of monoclonal antibodies which neutralize human metap-
neumovirus in vitro and in vivo. J Virol 2006;80:7799–806.
88. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-
neutralization of four paramyxoviruses by a human monoclonal antibody.
Nature 2013;501:439–43.
89. Deffrasness C, Hamelin ME, Prince GA, Boivin G. Identiﬁcation and evaluation
of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob
Agents Chemother 2008;52:279–87.
90. Deffrasnes C, Cavanagh MH, Goyette N, Cui K, Ge Q, Seth S, et al. Inhibition of
human metapneumovirus replication by small interfering RNA. Antivir Ther
2008;13:821–32.
91. Darniot M, Schildgen V, Schildgen O, Sproat B, Kleines M, Ditt V, et al. RNA
interference in vitro and in vivo using Dsi RNA targeting the nucleocapsid N
mRNA of human metapneumovirus. Antiviral Res 2012;93:364–73.
92. Hamelin ME, Couture C, Sackett MK, Boivin G. Enhanced lung disease and Th2
response following human metapneumovirus infection in mice immunized
with the inactivated virus. J Gen Virol 2007;88:3391–400.
93. Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindle RW. Cytotoxic
T-lymphocyte epitope vaccination protects against human metapneumovirus
infection and disease in mice. J Virol 2006;80:2034–44.
94. Tang RS, Schickli JH, MacPhail M, Fernandes F, Bicha L, Spaete J, et al. Effects of
human metapneumovirus and respiratory syncytial virus antigen insertion in
two 30 proximal genome positions of bovine/human parainﬂuenza virus type 3
on virus replication and immunogenicity. J Virol 2003;77:10819–28.
95. Skiadopolous MH, Biacchesi S, Buchholz UJ, Amaro-Carambot E, Surman SR,
Collins PL, et al. Individual contributions of the human metapneumovirus F, G,
and SH surface glycoproteins to the induction of neutralizing antibodies and
protective immunity. Virology 2006;345:492–501.
96. Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe Jr JE, Williams JV. Human
metapneumovirus fusion protein vaccines that are immunogenic and protec-
tive in cotton rats. J Virol 2007;81:698–707.
97. Herfst S, de Graaf M, Schrauwen EJ, Ulbrandt ND, Barnes AS, Senthil K, et al.
Immunization of Syrian golden hamsters with F subunit vaccine of human
metapneumovirus induces protection against challenge with homologous or
heterologous strains. J Gen Virol 2007;88:2702–9.
98. Herfst S, Schrauwen EJ, de Graaf M, van Amerongen G, van den Hoogen BG, de
Swart RL, et al. Immunogenicity and efﬁcacy of two candidate human metap-
neumovirus vaccines in cynomolgus macaques. Vaccine 2008;26:4224–30.
99. Levy C, Aerts L, Hamelin ME, Granier C, Szecsi J, Lavillette D, et al. Virus like
particle vaccine induces cross protection against human metapneumovirus
infection in mice. Vaccine 2013;31:2778–85.
100. Smith K. The use of plasmid-based reverse genetics to generate inﬂuenza virus
strains for improved vaccine production. MMG 445 Basic Biotechnology eJour-
nal 2007;3:123–30.
101. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ.
Infection of nonhuman primates with recombinant human metapneumovirus
lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory
protein and identiﬁes vaccine candidates. J Virol 2005;79:12608–13.
102. Liu P, Shu Z, Qin X, Dou Y, Zhao Y, Zhao X. A live attenuated human
metapneumovirus vaccine strain provides complete protection against ho-
mologous viral infection and cross-protection against heterologous viral
infection in BALB/c Mice. Clin Vaccine Immunol 2013;20:1246–54.
